February 1, 2015 12:54 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Speaking on
CNBC's Fast Money, Ritu Baral of Cowen and Company said that
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) is a buy. The company has received a breakthrough status by the FDA and it is about to start a phase 3 in the NASH program, said Baral. She added that we are going to see a filing for a lead program that has a potential to get approved by the FDA at the end of 2015 or early 2016.She likes
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) because of Parkinson's psychosis treatment, which has a billion plus market. It has a breakthrough status by the FDA and the company has been a topic in numerous acquisition discussions.Baral is bullish on
Raptor Pharmaceutical Corp. (NASDAQ: RPTP). The stock has been struggling recently because of the weak Q4, but Baral thinks that the catalyst for this stock will come in May when the data of pediatric NASH program gets released.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.